Summary
Spark therapeutics, Inc. (Spark) is a pharmaceutical company that offers development of gene therapy products for the treatment of debilitating genetic diseases such as inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases. It seeks to improve the lives of patients suffering from debilitating genetic diseases by developing one-time, life-altering treatments. The company concentrates on developing drugs for orphan diseases for which only palliative therapies exist. Spark’s pipeline products include SPK-RPE65 (Phase III) and a product candidate (IND-enabling studies) for the treatment of inherited retinal dystrophies; SPK-FIX (IND-enabling studies) for hemophilia B and another product candidate for hemophilia A; and an undisclosed candidate (preclinical) for the treatment of neurodegenerative diseases. The company is also developing GTO38, a lead therapeutic of Genable Technologies in collaboration, for the treatment of rhodopsin-linked autosomal dominant retinitis pigmentosa. Spark is headquartered in Philadelphia, Pennsylvania, the US.
Spark Therapeutics, Inc. (ONCE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Spark Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Spark Therapeutics, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Spark Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Spark Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Spark Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Spark Therapeutics, Inc., Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Spark Therapeutics Raises USD73 Million in Series B Financing 11
Spark Therapeutics Raises US$50 Million In Venture Financing 13
Genable Technologies Secures US$6.8 Million In Series B Financing 14
Partnerships 15
Spark Therapeutics Enters into Co-Development Agreement with Pfizer 15
Licensing Agreements 16
Spark Therapeutics Enters into Option Agreement with Clearside Biomedical to License Gene Therapy 16
Spark Therapeutics Enters Into Licensing Agreement With Genable Technologies 17
Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania for Proviral Plasmids 19
Spark Therapeutics Enters into Licensing Agreement with University of Iowa Research Foundation 21
Spark Therapeutics Enters into Licensing Agreement with Children’s Hospital of Philadelphia 23
Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania 25
Benitec Biopharma Enters Into Licensing Agreement With Genable Technologies 27
Equity Offering 28
Spark Therapeutics Prices Public Offering of Shares for USD94 Million 28
Spark Therapeutics Raises USD185 Million in IPO 30
Acquisition 32
Spark Therapeutics Acquires Genable Technologies for USD15.2 Million 32
Spark Therapeutics, Inc. - Key Competitors 34
Key Employees 35
Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37
List of Tables
Spark Therapeutics, Inc., Pharmaceuticals & Healthcare, Key Facts, 2014 1
Spark Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Spark Therapeutics, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Spark Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Spark Therapeutics, Inc., Deals By Therapy Area, 2010 to YTD 2016 8
Spark Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Spark Therapeutics Raises USD73 Million in Series B Financing 11
Spark Therapeutics Raises US$50 Million In Venture Financing 13
Genable Technologies Secures US$6.8 Million In Series B Financing 14
Spark Therapeutics Enters into Co-Development Agreement with Pfizer 15
Spark Therapeutics Enters into Option Agreement with Clearside Biomedical to License Gene Therapy 16
Spark Therapeutics Enters Into Licensing Agreement With Genable Technologies 17
Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania for Proviral Plasmids 19
Spark Therapeutics Enters into Licensing Agreement with University of Iowa Research Foundation 21
Spark Therapeutics Enters into Licensing Agreement with Children’s Hospital of Philadelphia 23
Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania 25
Benitec Biopharma Enters Into Licensing Agreement With Genable Technologies 27
Spark Therapeutics Prices Public Offering of Shares for USD94 Million 28
Spark Therapeutics Raises USD185 Million in IPO 30
Spark Therapeutics Acquires Genable Technologies for USD15.2 Million 32
Spark Therapeutics, Inc., Key Competitors 34
Spark Therapeutics, Inc., Key Employees 35
Spark Therapeutics, Inc., Subsidiaries 36
List of Figures
Spark Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Spark Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Spark Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Spark Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Spark Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Spark Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Spark Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Spark Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8